@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB01104 rdf:type ns2:Drug ; ns2:description "Sertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D₂ or histamine H₁ receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT_1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT_1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Sertraline may be used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (social phobia). "@en ; ns2:dosage , , , , , , , , , , , , , , , ; ns2:generalReferences "# Couzin J: The brains behind blockbusters. Science. 2005 Jul 29;309(5735):728. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16051786 # Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995 Nov 1;38(9):592-602. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8573661 # Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ: Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 1999 Apr;19(2):172-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10211919 # Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000 Apr 12;283(14):1837-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10770145 # Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24;278(12):983-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9307345 # Shelton RC: The role of sertraline in the management of depression. Clin Ther. 1994 Sep-Oct;16(5):768-82; discussion 767. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7859236 # Murdoch D, McTavish D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1281075"@en ; ns2:group "approved"@en ; ns2:halfLife "The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours. "@en ; ns2:indication "For the management of major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder with or without agoraphobia, premenstrual dysphoric disorder, social phobia, premature ejaculation, and vascular headaches."@en . @prefix owl: . @prefix ns4: . ns1:DB01104 owl:sameAs ns4:DB01104 . @prefix ns5: . ns1:DB01104 owl:sameAs ns5:DB01104 . @prefix dcterms: . ns1:DB01104 dcterms:title "Sertraline"@en . @prefix adms: . ns1:DB01104 adms:identifier . @prefix ns8: . ns1:DB01104 adms:identifier ns8:DB01104 , . @prefix ns9: . ns1:DB01104 adms:identifier ns9:D02360 , . @prefix ns10: . ns1:DB01104 adms:identifier ns10:C07246 , . @prefix ns11: . ns1:DB01104 adms:identifier ns11:PA451333 , . @prefix ns12: . ns1:DB01104 adms:identifier ns12:Sertraline ; ns2:mechanismOfAction "The exact mechanism of action sertraline is not fully known, but the drug appears to selectively inhibit the reuptake of serotonin at the presynaptic membrane. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission. It is suggested that these modifications are responsible for the antidepressant action observed during long term administration of antidepressants. It has also been hypothesized that obsessive-compulsive disorder is caused by the dysregulation of serotonin, as it is treated by sertraline, and the drug corrects this imbalance."@en ; ns2:packager , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ; ns2:patent , , ; ns2:routeOfElimination "Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination."@en ; ns2:synonym "Sertraline"@en , "Sertralina"@en , "(+)-Sertraline"@en , "CP 51974"@en , "Sertralinum"@en , "(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine"@en , "cis-(+)-Sertraline"@en , "(1S,4S)-Sertraline"@en ; ns2:toxicity "Symptoms of toxicity include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome. The most frequently observed side effects include: GI effects such as nausea, diarrhea or loose stools, dyspepsia, and dry mouth; nervous system effects such as somnolence, dizziness, insomnia, and tremor; sexual dysfunction in males (principally ejaculatory delay); and sweating."@en . @prefix ns13: . ns1:DB01104 ns13:hasAHFSCode ; ns2:foodInteraction "Avoid taking with grapefruit juice."@en , "Take with food."@en , "Avoid St.John's Wort."@en , "Avoid alcohol."@en ; ns2:proteinBinding "98% bound to serum proteins, principally to albumin and α₁-acid glycoprotein"@en ; ns2:salt " "@en ; ns2:synthesisReference "George J. Quallich, Michael T. Williams, \"Process for preparing sertraline intermediates.\" U.S. Patent US4839104, issued February, 1977."@en . @prefix ns14: . @prefix ns15: . ns1:DB01104 ns14:hasConcept ns15:M0029930 . @prefix foaf: . ns1:DB01104 foaf:page , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS . @prefix ns17: . ns1:DB01104 ns13:hasATCCode ns17:N06AB06 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "79617-96-2"@en ; ns2:category " "@en ; ns2:containedIn , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Melting-Point ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-basic- .